When sleep disturbance compounds depression...

Sinequan*
brand of doxepin
* Trade Mark
settles the mind for sleep while treating the underlying depression.

▶ Sedative tricyclic antidepressant.
▶ Once nightly dosage.

Indications: depression with or without anxiety. Contraindications: glaucoma, urinary retention, hypersensitivity to the drug. Side effects: dry mouth and drowsiness are most commonly reported. Precautions: Sinequan may potentiate other compounds e.g. monoamine oxidase inhibitors; not recommended in pregnancy or children under 12 years of age. Dosage: range 30mg to 300mg daily in divided doses; up to 100mg may be given as a single dose at night. Packs and Basic N.H.S. Cost: 10mg capsules (PL 57/5032) pack of 100 £2.98; 25mg capsules (PL 57/5033) pack of 100 £4.24; 50mg capsules (PL 57/5034) pack of 100 £7.01; 75mg capsules (PL 57/0133) pack of 60 £6.64.

Full information is available on request to the Company.
KEEP UP TO DATE

Helping Clumsy Children
Edited by Neil Gordon and Ian McKinlay
1980 212 pages illustrated paperback £5.95
Presents an integrated approach to the recognition, assessment and management of the clumsy child.

The Handicapped Child
A. H. Bowley and L. Gardner
1980 Fourth edition 256 pages illustrated paperback £6.50
Covers the educational, psychological and social problems of children with organically based handicaps and describes how their special needs can be met.

Clinical Neuropharmacology
(Monographs in Clinical Pharmacology)
Henn Kutt and Fletcher McDowell
1980 224 pages illustrated hardback £13.00
This new volume in the series presents a contemporary approach to drug therapy of the nervous system.

Neonatal Neurology
(Clinical Neurology and Neurosurgery Monographs Series)
G. M. Fenichel
1980 384 pages approx. illustrated hardback £14.00
Comprehensive coverage of the neurological malfunctions which may occur in the newborn.

• Scheduled for July Publication
Electrodiagnosis in Clinical Neurology
Edited by Michael J. Aminoff
1980 544 pages approx. illustrated hardback £24.00

• Scheduled for September Publication
Current Surgical Management of Neurologic Disease
Edited by Charles B. Wilson and Julian T. Hoff
1980 384 pages approx. illustrated hardback £13.00 approx.
CELLOLITE is a white, synthetic, X-Ray detectable sponge designed to overcome all the drawbacks of conventional absorbent materials.

The main characteristics of CELLOLITE — its extreme softness and high degree of conformability, its rapid wicking rate and high absorbency capacity, its overall X-Ray opacity and fibre-free nature, all serve to ensure that CELLOLITE is the only really safe and efficient sponge for Neurosurgery.

In short, no other material can match the properties of CELLOLITE.

Why struggle on using the same old fibrous pattie when you can take a giant step forward with CELLOLITE? In these days of Space Age surgical techniques why ‘make do’ with conventional patties?

Use CELLOLITE Surgical Sponges, the product born out of Space Age technology, and benefit from the superior properties of a sponge with the needs of the Twenty-first Century in mind.

Benefit from the softness and non-abrasive character, the overall X-Ray opacity possible due to ‘state of the art’ encapsulation of Barium Sulphate particles chemically bonded to the sponge, and, so important in delicate surgery, the fibre-free nature of CELLOLITE which guarantees that no fibres can be shed into the wound, virtually eliminating the risk of granulomas etc. which are a hazard when using conventional patties.

What other product can offer so much?

Use CELLOLITE the ideal Neurosurgical Sponge.

Smith & Nephew-Southalls Limited
Alum Rock Rd, Birmingham B8 3DY Telephone: 021-327-0204 Telex: 338340

Cellolite surgical sponges are made from *Merocel *Trade Mark of Americal Corporation
New Madopar 62.5 in Parkinson's Disease
Precision is the point.

Madopar has already changed the outlook of many patients with Parkinson's disease. The introduction of a new low-strength capsule, Madopar 62.5, offers an opportunity for others to benefit too. Some patients, especially the elderly, are very sensitive to the effects of Madopar and may find the usual starting dose of Madopar 125 simply too much to take. Others on long-term therapy experience fluctuations in performance which may be helped by administration of smaller, more frequent doses.¹ For these and other patients whose problems are dose-related the extra precision of Madopar 62.5 may well be the answer.

Madopar 250, 125 and now 62.5
levodopa plus benserazide
HOW TO DO IT

Every doctor knows the sinking sensation induced by waiting one's turn for an examination viva and the social anxieties of changing jobs. The misery of first night nerves does not, however, disappear with time: each decade brings new challenges. On these occasions—chairing a committee, giving evidence in court, appearing on television—practical tips can be enormously helpful. The same is true of the many skills not taught in medical school—how to lecture, referee papers, edit, or use a library. All these and many more nuggets of down-to-earth advice have been collected from past issues of the BMJ to form a compendium for the novice—whatever his or her age or seniority.

Price: Inland £4.00;
    Abroad US$10.00
(Concessionary price to BMA members: Inland £3.50;
    Abroad US$8.75.

When ordering BMA members must quote their membership number or the full price will be applicable.)

Payment must be enclosed with order or a surcharge of 50p will be made for rendering invoices and statements.

Order your copy now
From: The Publisher
    British Medical Journal
    BMA House
    Tavistock Square
    London WC1H 9JR
or any leading bookseller